JP5851516B2 - ケトライド化合物 - Google Patents

ケトライド化合物 Download PDF

Info

Publication number
JP5851516B2
JP5851516B2 JP2013542630A JP2013542630A JP5851516B2 JP 5851516 B2 JP5851516 B2 JP 5851516B2 JP 2013542630 A JP2013542630 A JP 2013542630A JP 2013542630 A JP2013542630 A JP 2013542630A JP 5851516 B2 JP5851516 B2 JP 5851516B2
Authority
JP
Japan
Prior art keywords
compound
formula
thiadiazol
pyridin
isoxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013542630A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544877A5 (cg-RX-API-DMAC10.html
JP2013544877A (ja
Inventor
バーラト トリヴェディ
バーラト トリヴェディ
プラサッド デシュパンデ
プラサッド デシュパンデ
ラヴィクマル タディパルティ
ラヴィクマル タディパルティ
スニル グプタ
スニル グプタ
サントシュ ディワカル
サントシュ ディワカル
シヴァジ パワル
シヴァジ パワル
ヴィジャイ パティル
ヴィジャイ パティル
デーパック デカネ
デーパック デカネ
マヘシュ パテル
マヘシュ パテル
サティシュ バブサー
サティシュ バブサー
アミット ミシュラ
アミット ミシュラ
マニッシュ ソランキ
マニッシュ ソランキ
モハンマド ジャフリ
モハンマド ジャフリ
サチン バグワット
サチン バグワット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wockhardt Ltd
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of JP2013544877A publication Critical patent/JP2013544877A/ja
Publication of JP2013544877A5 publication Critical patent/JP2013544877A5/ja
Application granted granted Critical
Publication of JP5851516B2 publication Critical patent/JP5851516B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013542630A 2010-12-09 2011-02-03 ケトライド化合物 Expired - Fee Related JP5851516B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3352/MUM/2010 2010-12-09
IN3352MU2010 2010-12-09
PCT/IB2011/050464 WO2012076989A1 (en) 2010-12-09 2011-02-03 Ketolide compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015135252A Division JP6102991B2 (ja) 2010-12-09 2015-07-06 ケトライド化合物

Publications (3)

Publication Number Publication Date
JP2013544877A JP2013544877A (ja) 2013-12-19
JP2013544877A5 JP2013544877A5 (cg-RX-API-DMAC10.html) 2014-03-20
JP5851516B2 true JP5851516B2 (ja) 2016-02-03

Family

ID=54259620

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013542630A Expired - Fee Related JP5851516B2 (ja) 2010-12-09 2011-02-03 ケトライド化合物
JP2015135252A Expired - Fee Related JP6102991B2 (ja) 2010-12-09 2015-07-06 ケトライド化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015135252A Expired - Fee Related JP6102991B2 (ja) 2010-12-09 2015-07-06 ケトライド化合物

Country Status (18)

Country Link
US (2) US9175031B2 (cg-RX-API-DMAC10.html)
EP (2) EP3216798A3 (cg-RX-API-DMAC10.html)
JP (2) JP5851516B2 (cg-RX-API-DMAC10.html)
KR (1) KR101657751B1 (cg-RX-API-DMAC10.html)
CN (2) CN103384676B (cg-RX-API-DMAC10.html)
AU (1) AU2011340204B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013014392B1 (cg-RX-API-DMAC10.html)
CA (2) CA2820451C (cg-RX-API-DMAC10.html)
DK (1) DK2673285T3 (cg-RX-API-DMAC10.html)
ES (1) ES2642287T3 (cg-RX-API-DMAC10.html)
HU (1) HUE036658T2 (cg-RX-API-DMAC10.html)
MX (1) MX348084B (cg-RX-API-DMAC10.html)
NZ (1) NZ623574A (cg-RX-API-DMAC10.html)
PL (1) PL2673285T3 (cg-RX-API-DMAC10.html)
PT (1) PT2673285T (cg-RX-API-DMAC10.html)
RU (1) RU2601550C2 (cg-RX-API-DMAC10.html)
WO (1) WO2012076989A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201304150B (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587490A (en) * 2010-08-20 2013-03-28 Greentide Ltd Anti-Microbial Compounds containing compounds with a sugar substituent
EP2688900B1 (en) * 2011-03-22 2016-09-28 Wockhardt Limited Process for preparation of ketolide compounds
US9346828B2 (en) 2013-06-07 2016-05-24 Wisconsin Alumni Research Foundation Forazolines, compositions thereof and uses thereof
NZ739211A (en) * 2015-07-27 2019-05-31 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
BR112017027798B1 (pt) 2015-07-27 2023-12-19 Chong Kun Dang Pharmaceutical Corp Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
HRP20230052T1 (hr) 2015-07-27 2023-03-03 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
HRP20220003T1 (hr) 2015-08-04 2022-04-01 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži
FI3362445T3 (fi) 2015-10-12 2023-03-21 Chong Kun Dang Pharmaceutical Corp Oksadiatsoliamiinijohdannaisyhdisteitä histonideasetylaasi 6:n inhibiittoreina ja niitä käsittävä farmaseuttinen koostumus
KR20180101509A (ko) * 2016-01-12 2018-09-12 욱크하르트 리미티드 약학 조성물
AU2017206671A1 (en) * 2016-01-12 2018-08-23 Wockhardt Limited Pharmaceutical compositions for the treatment of bacterial infections
WO2017122127A1 (en) * 2016-01-12 2017-07-20 Wockhardt Limited Pharmaceutical compositions
KR20190129863A (ko) * 2017-03-16 2019-11-20 욱크하르트 리미티드 케톨라이드 화합물의 제조 방법
KR102316234B1 (ko) 2018-07-26 2021-10-22 주식회사 종근당 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물
CN113874369B (zh) 2019-05-31 2024-08-27 株式会社钟根堂 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑高邻苯二甲酰亚胺衍生化合物及包含其的药物组合物
US20230029266A1 (en) 2019-11-05 2023-01-26 Dermira, Inc. MrgprX2 Antagonists for the Treatment of Inflammatory Disorders
AU2020380926B2 (en) * 2019-11-05 2026-07-16 Dermira, Inc. MrgprX2 antagonists and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2473525A1 (fr) 1980-01-11 1981-07-17 Roussel Uclaf Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
DE69733439T2 (de) 1996-09-04 2006-05-04 Abbott Laboratories, Abbott Park 6-o-Substituierte Ketoliden mit antibakteriellen Wirkung
JP2004514643A (ja) * 1997-10-29 2004-05-20 大正製薬株式会社 エリスロマイシンa誘導体
HRP980189B1 (en) * 1998-04-06 2004-04-30 Pliva Pharm & Chem Works Novel 15-membered lactams ketolides
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
MXPA03001607A (es) 2000-08-22 2003-06-04 Basilea Pharmaceutica Ag Nuevos macrolidos con actividad antibacteriana.
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
JP2004531471A (ja) * 2000-12-21 2004-10-14 グラクソ グループ リミテッド マクロライド抗生物質
GB0127349D0 (en) 2001-11-14 2002-01-02 Glaxo Group Ltd Macrolides
US6995143B2 (en) * 2002-02-28 2006-02-07 Basilea Pharmaceutica Ag Macrolides with antibacterial activity
US6727229B2 (en) 2002-08-19 2004-04-27 Enanta Pharmaceuticals, Inc. 11,12-substituted lactone ketolide derivatives having antibacterial activity
WO2004108744A2 (en) * 2003-05-19 2004-12-16 Prasad K Deshpande Azalides and azaketolides having antimicrobial activity
WO2006080954A1 (en) * 2004-07-28 2006-08-03 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
CN101541331A (zh) * 2006-08-24 2009-09-23 沃克哈特研究中心 具有抗微生物活性的新颖大环内酯和酮内酯
MX2010002932A (es) * 2007-09-17 2010-05-27 Enanta Pharm Inc Macrolidos de biarilo con puente en 6, 11.
US8552162B2 (en) 2008-05-09 2013-10-08 Enanta Pharmaceuticals, Inc. Processes for the preparation of 2 fluoro 6-11 bicyclic erythromycin derivatives
EP2435460B1 (en) * 2009-05-27 2015-01-07 Wockhardt Limited Ketolide compounds having antimicrobial activity

Also Published As

Publication number Publication date
EP3216798A3 (en) 2017-10-25
PT2673285T (pt) 2017-10-19
MX348084B (es) 2017-05-26
CA2820451C (en) 2017-12-12
EP3216798A2 (en) 2017-09-13
CN103384676B (zh) 2016-02-03
KR20130112911A (ko) 2013-10-14
BR112013014392A2 (pt) 2016-07-19
RU2601550C2 (ru) 2016-11-10
EP2673285A1 (en) 2013-12-18
MX2013006461A (es) 2013-10-01
JP2015172085A (ja) 2015-10-01
JP2013544877A (ja) 2013-12-19
ES2642287T3 (es) 2017-11-16
AU2011340204B2 (en) 2016-04-14
US20140005133A1 (en) 2014-01-02
HUE036658T2 (hu) 2018-07-30
NZ623574A (en) 2015-07-31
PL2673285T3 (pl) 2017-12-29
US9175031B2 (en) 2015-11-03
CN105669803A (zh) 2016-06-15
CN103384676A (zh) 2013-11-06
ZA201304150B (en) 2014-11-26
RU2013131234A (ru) 2015-01-20
DK2673285T3 (en) 2017-10-16
WO2012076989A1 (en) 2012-06-14
JP6102991B2 (ja) 2017-03-29
CA2820451A1 (en) 2012-06-14
US20160083412A1 (en) 2016-03-24
EP2673285B1 (en) 2017-07-19
BR112013014392B1 (pt) 2021-09-21
AU2011340204A1 (en) 2013-07-04
CA2964104A1 (en) 2012-06-14
KR101657751B1 (ko) 2016-09-19

Similar Documents

Publication Publication Date Title
JP6102991B2 (ja) ケトライド化合物
JP3000023B2 (ja) 新規なエリスロマイシン誘導体、それらの製造法及び薬剤としての使用
CN102459296B (zh) 具有抗微生物活性的酮内酯类化合物
CZ9904388A3 (cs) 9-Oximové deriváty erythromycinu
HUP0002209A2 (hu) 4-Szubsztituált-9-dezoxo-9A-aza-9A-homoeritromicin-származékok és e vegyületeket tartalmazó gyógyászati készítmények
HRP20010374A2 (en) 13-membered azalides and their use as antibiotic agents
EP1137654A1 (en) Carbamate and carbazate ketolide antibiotics
JP2000159790A (ja) 新規のエリスロマイシン誘導体、それらの製造方法及びそれらの薬剤としての使用
NZ611653A (en) Ketolide compounds
NZ611653B (en) Ketolide compounds
JP2004331632A (ja) 2−フルオロ−6−o−置換ケトライド誘導体
JP2007254285A (ja) 2−フルオロ−6−o−置換ケトライド誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140131

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150706

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151202

R150 Certificate of patent or registration of utility model

Ref document number: 5851516

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees